-

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Super Micro Computer, Inc. (SMCI)

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Super Micro Computer, Inc. (“Super Micro Computer” or the “Company”) (NASDAQ: SMCI). The investigation concerns whether Super Micro Computer and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

[Click here to learn more about the investigation]

On August 27, 2024, the investor research firm Hindenburg Research released a report that detailed alleged “accounting red flags, evidence of undisclosed related party transactions, sanctions and export control failures, and customer issues” at behalf of Super Micro Computer. On this news, the price of Super Micro shares declined by $14.87 per share, from $562.51 per share on August 26, 2024, to close at $547.64 on August 27, 2024.

On August 28, 2024, the day after Hindenburg Research published its report, Super Micro Computer disclosed that it would delay the filing of its annual report for its fiscal year that ended June 30, 2024. On this news, the price of Super Micro shares declined by $104.15 per share, or approximately 18.3%, to close at $443.49 on August 28, 2024.

If you purchased or otherwise acquired Super Micro Computer securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Industry:

Kirby McInerney LLP

NASDAQ:SMCI
Release Versions
English
$Cashtags
$SMCI
Hashtags
#Investigation
#Investor

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

VITAL FARMS, INC. ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Vital Farms, Inc. (“Vital Farms” or the “Company”) (NASDAQ:VITL) securities during the period of May 8, 2025 through February 26, 2026, inclusive (“the Class Period”). If you suffered a loss on your Vital Farms investments, you have until May 26, 2026 to request lead plaintiff appointment. For more information: [CONTACT THE FIRM IF YOU SUFFERED...

ADMA BIOLOGICS, INC. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ:ADMA). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On March 24, 2026, Culper Research published a report on ADMA alleging “Channel Stuffing, an Undisclos...

IBRX ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of ImmunityBio, Inc. Investors

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) securities during the period of January 19, 2026 through March 24, 2026, inclusive (“the Class Period”). If you suffered a loss on your ImmunityBio investments, you have until May 26, 2026 to request lead plaintiff appointment. For more information: [CONTACT THE FIRM IF YOU SUFFERE...
Back to Newsroom